FDA approves therapy for GSDIa - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA approves therapy for GSDIa

The one-time gene therapy is intended to restore the deficient enzyme needed to release stored glucose during fasting.

  • By

  • Kathryn Wighton

  • August 20, 2026

  • 2 min

Share

Clinical Report: FDA approves therapy for GSDIa

Overview

The FDA has granted accelerated approval to pariglasgene brecaparvovec-opnr (Genglycos) for reducing daily cornstarch intake in patients aged 8 years and older with glycogen storage disease type Ia.

Background

Glycogen storage disease type Ia is caused by glucose-6-phosphatase deficiency, leading to hypoglycemia and long-term metabolic complications. Current management strategies focus on dietary modifications and cornstarch supplementation to maintain euglycemia.

Data Highlights

OutcomePariglasgene Brecaparvovec-opnrPlacebo
Mean reduction in daily cornstarch intake31%0%
Mean decrease in daily cornstarch doses1 dose0 doses
Mean increase in hypoglycemic glucose values3%N/A

Key Findings

  • Pariglasgene brecaparvovec-opnr is the first approved therapy for glycogen storage disease type Ia.
  • The therapy achieved a statistically significant 31% mean reduction in daily cornstarch intake compared to placebo.
  • Patients treated with the therapy had a mean decrease of one daily cornstarch dose from baseline compared to placebo.
  • Serious adverse reactions included anaphylaxis, adrenal insufficiency, and elevated lactate levels.
  • 29% of patients treated experienced hypertriglyceridemia compared to 8% in the placebo group.
  • The therapy is contraindicated during pregnancy.

Clinical Implications

Ongoing monitoring for adverse reactions is essential, given the reported serious side effects.

Conclusion

The accelerated approval of pariglasgene brecaparvovec-opnr offers a new treatment option for managing glycogen storage disease type Ia.

Related Resources & Content

  1. FDA, FDA, 2026 -- FDA Approves First Therapy for Patients aged 8 years and older with Glycogen Storage Disease Type Ia
  2. Endocrine Abstracts, ECEESPE2025 -- Efficacy and safety results from a pivotal phase 3 trial of DTX401
  3. MDSpire News — FDA Approves Low-IgA IG Therapy
  4. glaucoma physician — FDA Grants SPA for Phase 3 Trial of Dazdotuftide
  5. reuters — FDA Approves Expanded Use of Gene Therapy for Duchenne Muscular Dystrophy
  6. the medicine maker — This Week’s CGT News: Duchenne Gene Therapy Hits Pivotal Mark
  7. FDA Approves First Therapy for Patients aged 8 years and older with Glycogen Storage Disease Type Ia | FDA
  8. Efficacy and safety results from a pivotal phase 3 trial of DTX401, an AAV8-mediated liver-directed gene therapy, in individuals with glycogen storage disease type Ia (GSDIa) | ECEESPE2025 | Joint Congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE) 2025: Connecting Endocrinology Across the Life Course | Endocrine Abstracts
  9. Glycogen Storage Disease Type I

Original Source(s)

FDA approves therapy for GSDIa

  • by Kathryn Wighton

  • August 20, 2026

Related Content

HHS Ends Federal Medicaid and CHIP Funding for Sex-Rejecting Procedures for Children and Youth

SCPC Care: Non-Age-Related Factors Contribute to Timing

A literature review published in Future Cardiology suggests that providers should look beyond chronological age to various modifiable physiologic factors when planning a superior cavopulmonary connection (SCPC) procedure.

  • by

  • August 12, 2026

  • 6 min
American Epilepsy Society Clinical Practice Guideline: Infantile Epilepsy

This American Epilepsy Society (AES) practice guideline provides updated, evidence-based recommendations for the management of epilepsy in infants and children aged 1 month to <36 months.

  • by

  • August 14, 2026

  • 2 min